Solid Biosciences Licenses AAV-SLB101 to Kinea Bio for Muscular Dystrophy Gene Therapy

CHARLESTOWN, Mass., Sept. 23, 2025 – Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on genetic medicines for neuromuscular and cardiac diseases, has announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio. The agreement will allow Kinea Bio to use Solid’s proprietary, next-generation AAV capsid, AAV-SLB101, for the development and commercialization of its investigational gene therapy, KNA-155. This therapy is aimed at treating dysferlinopathy, a form of limb-girdle muscular dystrophy.

Under the terms of the agreement, Solid will receive an upfront fee and will be eligible for additional payments based on development and sales milestones, as well as tiered royalties on net sales.

The AAV-SLB101 capsid, a key component of a viral delivery system, was designed to have enhanced muscle tropism (attraction to muscle tissue) and reduced biodistribution to the liver. Preclinical studies and early clinical data from Solid’s ongoing Phase 1/2 INSPIRE DUCHENNE trial, which is evaluating SGT-003, have demonstrated its ability to effectively deliver genetic material to cardiac and skeletal muscle.

According to Solid Biosciences President and CEO Bo Cumbo, the company is “highly encouraged by the emerging safety profile” of AAV-SLB101 in the INSPIRE DUCHENNE trial, which he believes “continues to de-risk and build the value proposition” of the capsid.

Kinea Bio’s CEO, Casey Childers, also expressed confidence in the partnership, stating that Solid’s AAV-SLB101 “will provide a powerful delivery mechanism for our KNA-155 program.” The company is using the preclinical and clinical data from AAV-SLB101 to advance its therapy toward a potential safe and effective treatment for patients with dysferlinopathies.

Solid Biosciences aims to broadly license AAV-SLB101 to other companies and academic institutions. The company already has licensing agreements with more than 25 academic labs, institutions, and companies for the use of its technology.